Provided by Tiger Trade Technology Pte. Ltd.

Biocryst Pharmaceuticals

10.09
-0.0800-0.79%
Pre-market: 10.190.1000+0.99%06:17 EDT
Volume:1.97M
Turnover:19.88M
Market Cap:2.58B
PE:-6.70
High:10.22
Open:10.15
Low:9.94
Close:10.17
52wk High:11.22
52wk Low:6.00
Shares:255.54M
Float Shares:222.00M
Volume Ratio:0.68
T/O Rate:0.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.5054
EPS(LYR):1.21
ROE:587.33%
ROA:52.86%
PB:-5.68
PE(LYR):8.34

Loading ...

Jun 14, 2024

Proposed Sale Of Securities

Form 144 - Report of proposed sale of securities
Jun 13, 2024

Major Issues Report

Form 8-K - Current report
May 07, 2024

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
May 06, 2024

Major Issues Report

Form 8-K - Current report
Feb 27, 2024

Annual Report

Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405]
Feb 26, 2024

Major Issues Report

Form 8-K - Current report
Feb 15, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
Feb 14, 2024

Beneficial Ownership Change

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
Jan 18, 2024

Major Issues Report

Form 8-K - Current report
Jan 08, 2024

Major Issues Report

Form 8-K - Current report
Dec 01, 2023

Major Issues Report

Form 8-K - Current report
Nov 30, 2023

Major Issues Report

Form 8-K - Current report
Nov 08, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]
Nov 08, 2023

Employee Stock Ownership

Form S-8 - Securities to be offered to employees in employee benefit plans
Nov 04, 2023

Major Issues Report

Form 8-K - Current report
Nov 04, 2023

Major Issues Report

Form 8-K - Current report
Nov 02, 2023

Major Issues Report

Form 8-K - Current report
Oct 26, 2023

Major Issues Report

Form 8-K - Current report
Aug 08, 2023

Quarterly Report

Form 10-Q - Quarterly report [Sections 13 or 15(d)]